Stock Track | Syndax Pharmaceuticals Plunges 6.67% After-Hours on Mixed Q1 Earnings with Sales Miss

Stock Track04:40

Syndax Pharmaceuticals' stock experienced a significant after-hours plunge of 6.67%, following the release of its first-quarter 2026 financial results.

The company reported a mixed earnings performance, with its loss per share of $(0.48) beating analyst estimates of $(0.64). However, quarterly sales of $64.864 million fell short of the consensus estimate of $70.439 million, representing a miss of approximately 7.91%.

While the company demonstrated substantial year-over-year revenue growth of over 223%, the sales shortfall appears to have prompted a negative reaction from investors in the after-hours session, leading to the sharp decline in share price.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1101438220?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-01 04:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1101438220","market":"us","top_or_hot":-1,"title":"Stock Track | Syndax Pharmaceuticals Plunges 6.67% After-Hours on Mixed Q1 Earnings with Sales Miss","media":"Stock Track","content":"<p>Syndax Pharmaceuticals' stock experienced a significant after-hours plunge of 6.67%, following the release of its first-quarter 2026 financial results.</p><p>The company reported a mixed earnings performance, with its loss per share of $(0.48) beating analyst estimates of $(0.64). However, quarterly sales of $64.864 million fell short of the consensus estimate of $70.439 million, representing a miss of approximately 7.91%.</p><p>While the company demonstrated substantial year-over-year revenue growth of over 223%, the sales shortfall appears to have prompted a negative reaction from investors in the after-hours session, leading to the sharp decline in share price.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Syndax Pharmaceuticals Plunges 6.67% After-Hours on Mixed Q1 Earnings with Sales Miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Syndax Pharmaceuticals Plunges 6.67% After-Hours on Mixed Q1 Earnings with Sales Miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-01 04:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Syndax Pharmaceuticals' stock experienced a significant after-hours plunge of 6.67%, following the release of its first-quarter 2026 financial results.</p><p>The company reported a mixed earnings performance, with its loss per share of $(0.48) beating analyst estimates of $(0.64). However, quarterly sales of $64.864 million fell short of the consensus estimate of $70.439 million, representing a miss of approximately 7.91%.</p><p>While the company demonstrated substantial year-over-year revenue growth of over 223%, the sales shortfall appears to have prompted a negative reaction from investors in the after-hours session, leading to the sharp decline in share price.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNDX","symbol_name":"Syndax Pharmaceuticals, Inc. ","start_time":0,"source_url":"","article_id":"1101438220","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1101438220","pubTimestamp":1777581601,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Syndax Pharmaceuticals' stock experienced a significant after-hours plunge of 6.67%, following the release of its first-quarter 2026 financial results.The company reported a mixed earnings...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SNDX":"Syndax Pharmaceuticals, Inc. "},"translate_title":"个股追踪|Syndax Pharmaceuticals盘后暴跌6.67%，Q1盈利好坏参半，销售未达预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNDX":1},"content_text":"Syndax Pharmaceuticals' stock experienced a significant after-hours plunge of 6.67%, following the release of its first-quarter 2026 financial results.The company reported a mixed earnings performance, with its loss per share of $(0.48) beating analyst estimates of $(0.64). However, quarterly sales of $64.864 million fell short of the consensus estimate of $70.439 million, representing a miss of approximately 7.91%.While the company demonstrated substantial year-over-year revenue growth of over 223%, the sales shortfall appears to have prompted a negative reaction from investors in the after-hours session, leading to the sharp decline in share price.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1101438220","isCrawlerRequest":true}